StoxDr. Lal Path Labs vs Syngene International: share price & financials comparison
NSE: LALPATHLAB vs SYNGENE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Lal Path Labs vs Syngene International at a glance
Dr. Lal Path Labs (LALPATHLAB) has a market capitalisation of ₹33,443 Cr, against ₹17,936 Cr for Syngene International (SYNGENE). Over the past year Dr. Lal Path Labs has returned +26.4%, compared with -31.3% for Syngene International. On valuation, Dr. Lal Path Labs trades at a lower P/E of 57.3 versus 469.5. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 0.8%). Dr. Lal Path Labs comes out ahead on size, valuation, profitability, growth, momentum and technicals. Across the scored metrics below, Dr. Lal Path Labs leads on 14 and Syngene International on 2. On StoxGud's 10-point checklist, Dr. Lal Path Labs scores 9/10 and Syngene International scores 3/10.
| Metric | Dr. Lal Path Labs | Syngene International |
|---|---|---|
| Size | ||
| Market cap | ₹33,443 Cr | ₹17,936 Cr |
| Revenue (latest FY) | ₹2,763 Cr | ₹3,739 Cr |
| Net profit (latest FY) | ₹505 Cr | ₹0 Cr |
| Valuation | ||
| P/E | 57.3 | 469.5 |
| P/B | 12.19 | 3.69 |
| Dividend yield | 0.67% | 0.28% |
| Profitability | ||
| Return on equity | 21.3% | 0.8% |
| Net profit margin | 19.2% | 1.1% |
| Operating margin | 29.5% | 21.3% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | -8.6% |
| Net profit growth (YoY) | +27.6% | — |
| Revenue CAGR (multi-year) | +11.8% | +11.3% |
| Financial health | ||
| Debt to equity | 0.00 | 0.01 |
| Momentum | ||
| 1-month return | +4.3% | +17.1% |
| 1-year return | +26.4% | -31.3% |
| 3-year CAGR | +15.0% | -14.4% |
| 5-year CAGR | +1.7% | -5.6% |
| 10-year CAGR | +13.7% | +5.1% |
| Distance from 52W high | -1.8% | -33.1% |
| Technicals | ||
| RSI (14) | 68 | 77 |
| Price vs 200-day avg | +19.8% | +5.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Lal Path Labs | Syngene International |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Lal Path Labs or Syngene International?
Dr. Lal Path Labs has a market cap of ₹33,443 Cr and Syngene International has a market cap of ₹17,936 Cr as of 13 Nov 2026.
Which has a lower P/E, Dr. Lal Path Labs or Syngene International?
Dr. Lal Path Labs has the lower P/E: Dr. Lal Path Labs trades at 57.3 and Syngene International at 469.5.
Which gave better returns in the last year, Dr. Lal Path Labs or Syngene International?
Dr. Lal Path Labs did better: Dr. Lal Path Labs returned +26.4% and Syngene International returned -31.3% over one year.
What is the difference between Dr. Lal Path Labs and Syngene International?
Both are NSE-listed companies in Healthcare. Dr. Lal Path Labs is about 1.9 times the size of Syngene International by market cap. In the latest financial year Dr. Lal Path Labs reported revenue of ₹2,763 Cr and Syngene International ₹3,739 Cr. Operating margin is 29.5% for Dr. Lal Path Labs and 21.3% for Syngene International. Debt to equity is 0.00 for Dr. Lal Path Labs and 0.01 for Syngene International.
Which is better, Dr. Lal Path Labs or Syngene International?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Dr. Lal Path Labs leads on 14 and Syngene International on 2. Dr. Lal Path Labs is ahead on size, valuation, profitability, growth, momentum and technicals. On StoxGud's rules-based checklist Dr. Lal Path Labs scores 9/10 and Syngene International scores 3/10. This is information, not advice: consult a SEBI-registered adviser before investing.